Dantron
Identification
- Name
- Dantron
- Accession Number
- DB04816
- Description
Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Withdrawn
- Structure
- Weight
- Average: 240.2109
Monoisotopic: 240.042258744 - Chemical Formula
- C14H8O4
- Synonyms
- 1,8-dihydroxy-9,10-anthracenedione
- 1,8-dihydroxy-9,10-anthraquinone
- 1,8-dihydroxyanthra-9,10-quinone
- 1,8-Dihydroxyanthrachinon
- 1,8-Dihydroxyanthraquinone
- Chrysazin
- Danthron
- Dantron
- Dantrona
- Dantrone
- Dantronum
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Dantron. Aclidinium The therapeutic efficacy of Dantron can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Dantron can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Dantron is combined with Alloin. Amantadine The therapeutic efficacy of Dantron can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Dantron. Amiodarone The therapeutic efficacy of Dantron can be decreased when used in combination with Amiodarone. Amitriptyline The therapeutic efficacy of Dantron can be decreased when used in combination with Amitriptyline. Amlodipine The therapeutic efficacy of Dantron can be decreased when used in combination with Amlodipine. Amobarbital The therapeutic efficacy of Dantron can be decreased when used in combination with Amobarbital. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- International/Other Brands
- Altan / Antrapurol / Bancon / Duolax / Prugol / Roydan / Scatron D / Zwitsalax
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Doss Tab Dantron (50 mg) + Docusate sodium (60 mg) Tablet Oral Smithkline Beecham Pharma Division Of Smithkline Beecham Inc 1993-12-31 1997-12-17 Canada Regulex D Cap Dantron (50 mg) + Docusate sodium (60 mg) Capsule Oral Whitehall Robins Inc. 1993-12-31 1998-07-29 Canada
Categories
- ATC Codes
- A06AB03 — Dantron
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anthraquinones. These are organic compounds containing either anthracene-9,10-quinone, 1,4-anthraquinone, or 1,2-anthraquinone.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Anthracenes
- Sub Class
- Anthraquinones
- Direct Parent
- Anthraquinones
- Alternative Parents
- Aryl ketones / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 9,10-anthraquinone / Anthraquinone / Aromatic homopolycyclic compound / Aryl ketone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- dihydroxyanthraquinone (CHEBI:3682) / Anthraquinone type (C10312)
Chemical Identifiers
- UNII
- Z4XE6IBF3V
- CAS number
- 117-10-2
- InChI Key
- QBPFLULOKWLNNW-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
- IUPAC Name
- 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione
- SMILES
- OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0029752
- KEGG Drug
- D07107
- KEGG Compound
- C10312
- PubChem Compound
- 2950
- PubChem Substance
- 46509077
- ChemSpider
- 2845
- BindingDB
- 11316
- 22293
- ChEBI
- 3682
- ChEMBL
- CHEMBL53418
- ZINC
- ZINC000003860369
- PharmGKB
- PA449206
- PDBe Ligand
- CHZ
- Wikipedia
- Danthron
- PDB Entries
- 3nsq
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Solution Buccal; Oral 5 g Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 193 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.305 mg/mL ALOGPS logP 2.98 ALOGPS logP 3.61 ChemAxon logS -2.9 ALOGPS pKa (Strongest Acidic) 9.09 ChemAxon pKa (Strongest Basic) -4.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 74.6 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 65.11 m3·mol-1 ChemAxon Polarizability 23.19 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9899 Blood Brain Barrier + 0.7514 Caco-2 permeable + 0.6963 P-glycoprotein substrate Non-substrate 0.5556 P-glycoprotein inhibitor I Non-inhibitor 0.9605 P-glycoprotein inhibitor II Non-inhibitor 0.9419 Renal organic cation transporter Non-inhibitor 0.8913 CYP450 2C9 substrate Non-substrate 0.7982 CYP450 2D6 substrate Non-substrate 0.9168 CYP450 3A4 substrate Non-substrate 0.7151 CYP450 1A2 substrate Inhibitor 0.8918 CYP450 2C9 inhibitor Inhibitor 0.775 CYP450 2D6 inhibitor Non-inhibitor 0.7456 CYP450 2C19 inhibitor Non-inhibitor 0.6159 CYP450 3A4 inhibitor Non-inhibitor 0.8357 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7605 Ames test AMES toxic 0.9261 Carcinogenicity Non-carcinogens 0.893 Biodegradation Not ready biodegradable 0.7278 Rat acute toxicity 2.8601 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9505 hERG inhibition (predictor II) Non-inhibitor 0.9192
Spectra
- Mass Spec (NIST)
- Download (8.11 KB)
- Spectra
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Skupinska K, Zylm M, Misiewicz I, Kasprzycka-Guttman T: Interaction of anthracene and its oxidative derivatives with human serum albumin. Acta Biochim Pol. 2006;53(1):101-12. Epub 2006 Jan 9. [PubMed:16404478]
Drug created on September 11, 2007 14:07 / Updated on June 12, 2020 10:52